Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Ultragenyx Pharmaceutical Q3 EPS $(1.81) Misses $(1.25) Estimate, Sales $159.933M Miss $166.709M Estimate

Author: Benzinga Newsdesk | November 04, 2025 04:10pm
Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.81) per share which missed the analyst consensus estimate of $(1.25) by 45.03 percent. This is a 29.29 percent decrease over losses of $(1.40) per share from the same period last year. The company reported quarterly sales of $159.933 million which missed the analyst consensus estimate of $166.709 million by 4.06 percent. This is a 14.65 percent increase over sales of $139.494 million the same period last year.

Posted In: RARE


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist